Skip to main content
Multiple Sclerosis Discovery Forum
Inspiring Connections
Utility Navigation
Feedback
Newsletter
RSS
Twitter
User Top Menu
Welcome, guest
Log In
Join
Why Join?
Search form
Search
About Us
Overview
Who We Are
Contact
Fan Mail
How to Cite
News & Future Directions
New Findings
News Briefs
Podcasts
News Synthesis
Essays & Opinions
Blogs
Papers
Editors' Picks
Classic Papers
Archive
Forums
Discussions
Webinars
Professional Resources
Meetings & Events
Past Meetings
Funding Opportunities
Jobs
Member Directory
Bulletin Board
Useful Links
Research Resources
Data Visualizations
Clinical Trials - Public Availability of Results
World Map
MS trials baseline
NMO History
NMO Galaxy
Map of MS Prevalence
Progressive MS Authors Galaxy
Word Cloud
MSLine
Ongoing Clinical Trials in MS
MRI-Related Clinical Trials
RRMS and CIS
Immunopathogenesis of MS
The MS Galaxy
ARR in Placebo Groups
Symptoms Prevalence
Scientific Literature TreeMap
Clinical Trials in MS
Drug-Development Pipeline
Tissue Repositories
MSGene
Animal Models
Clinical Trials
Click Here to Support MSDF
You are here
Home
Most Viewed
Momenta Pharmaceuticals Announces Launch of Glatopa(TM) (glatiramer acetate injection), the First Substitutable Generic for COPAXONE(R) (glatiramer acetate injection) 20mg
Phase 2 results of the RADIANCE trial: a randomized, double-blind, placebo-controlled trial of oral RPC1063 in relapsing multiple sclerosis
A pooled analysis of two phase 3 clinical trials of dalfampridine in patients with multiple sclerosis.
Neuroimmune Crosstalk in CNS Disorders: The Histamine Connection.
Kappa free light chains: diagnostic and prognostic relevance in MS and CIS.
Conference Report: Multiple Sclerosis Update: Hot topics from 5th Joint Triennial Congress of the European and Americas Committees for Treatment and Research in Multiple Sclerosis (ECTRIMS/ACTRIMS).
Neuropsychological Aspects of Childhood Multiple Sclerosis: An Overview.
Bag3-Induced Autophagy Is Associated with Degradation of JCV Oncoprotein, T-Ag.
Acute stress increases permeability of the blood-brain-barrier through activation of brain mast cells.
Cerebrospinal fluid anti-whole myelin antibodies are not correlated to magnetic resonance imaging activity in multiple sclerosis.
Epidermal pigmentation in the human lineage is an adaptation to ultraviolet radiation.
Alemtuzumab-based induction treatment versus basiliximab-based induction treatment in kidney transplantation (the 3C Study): a randomised trial.
Do positive or negative stressful events predict the development of new brain lesions in people with multiple sclerosis?
New TYSABRI® data show earlier treatment and longer-term use result in significant reductions in MS disease activity
A safety and pharmacokinetic study of intravenous natalizumab in patients with MS.
The Arabic version of the Mayo-Portland Adaptability Inventory 4: a validation study.
Clinical correlates of chronic cerebrospinal venous insufficiency in multiple sclerosis.
Onset of progressive phase is an age-dependent clinical milestone in multiple sclerosis.
Natalizumab use in pediatric patients with relapsing-remitting multiple sclerosis.
Association between Change in Normal Appearing White Matter Metabolites and Intrathecal Inflammation in Natalizumab-Treated Multiple Sclerosis.
A molecular link between the active component of marijuana and Alzheimer's disease pathology.
New data at AAN to confirm efficacy of Novartis' Gilenya® across four key measures of MS disease activity, including brain volume loss
Neuroprotective effects of riluzole in neurotrauma models: a review.
Comorbid Multiple Sclerosis and TDP-43 Proteinopathy in a Gulf War Sea Captain.
The Safety Profile of Dalfampridine Extended Release in Multiple Sclerosis Clinical Trials.
Pages
« first
‹ previous
…
173
174
175
176
177
178
179
180
181
…
next ›
last »